RAD Rite Aid Corporation

Rite Aid Expands Naloxone Dispensing Program in Four Additional States

Rite Aid announced today that naloxone, a medication that can be used to reverse the effects of an opioid overdose, is now available at more than 440 pharmacies in Kentucky, Ohio, Oregon and Vermont without a prescription, subject to state regulations. Previously, naloxone, which can be administered by injection or nasal spray, was only available with a physician’s prescription.

“According to the Centers for Disease Control and Prevention, 78 people die from an opioid overdose in the United States each day,” said Jocelyn Konrad, Rite Aid executive vice president of pharmacy. “Rite Aid is committed to helping reduce the number deaths due to opioid overdoses and making naloxone available without a prescription at our pharmacies in Kentucky, Ohio, Oregon and Vermont is an important action we can take in the fight against opioid abuse.”

Naloxone is also available for purchase without patient specific prescriptions at Rite Aid pharmacies in 13 additional states including: Alabama, California, Colorado, Connecticut, Idaho, Indiana, Massachusetts, Maryland, North Carolina, New Hampshire, New York, Pennsylvania and Rhode Island.

To date, Rite Aid has trained more than 10,000 pharmacists on naloxone dispensing. Rite Aid is also working to expand its naloxone dispensing program in other states served by the Company where naloxone is currently only available with a prescription.

Rite Aid Corporation (NYSE: RAD) is one of the nation's leading drugstore chains with nearly 4,600 stores in 31 states and the District of Columbia and fiscal 2016 annual revenues of $30.7 billion. Information about Rite Aid, including corporate background and press releases, is available through the company's website at www.riteaid.com.

EN
27/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rite Aid Corporation

Rite Aid Corporation: Rite Aid's bankruptcy accentuates drugstores' ne...

Drugstore retailers face many challenges including the need for scale to cover high fixed costs, high reimbursement risk, a growing number of online pharmacies and macroeconomic uncertainty.

Moody's downgrades Rite Aid's PDR to D-PD following Chapter 11 filing

Moody's Investors Service (Moody's) downgraded Rite Aid Corporation's ("Rite Aid") probability of default rating ("PDR") to D-PD from Caa3-PD. Moody's also downgraded the company's corporate family rating ("CFR") to Caa3 from Caa2, its senior secured ABL revolving credit facility rating to Caa1 from...

Rite Aid Corporation: Update following downgrade to Caa2 CFR and Caa3-...

Our credit view of Rite Aid reflects its weak interest coverage and 2025 debt maturities as well as its adequate liquidity and positive longer term trends of the prescription drug industry.

Moody's downgrades Rite Aid's CFR to Caa2; PDR to Caa3-PD

Moody's Investors Service ("Moody's") today downgraded Rite Aid Corporation's ("Rite Aid") corporate family rating ("CFR") to Caa2 from B3 and its probability of default rating ("PDR") to Caa3-PD from B3-PD. Moody's also downgraded the rating of Rite Aid's senior secured asset based revolving credit...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch